2100 Wharton Street
Suite 701
Pittsburgh, PA 15203
United States
412 586 5830
https://www.krystalbio.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 229
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, President & CEO | 1,32M | S.O. | 1965 |
Ms. Suma M. Krishnan | Founder, President of R&D and Director | 895,33k | S.O. | 1965 |
Ms. Kathryn A. Romano | Executive VP & Chief Accounting Officer | 614,87k | 2,35M | 1982 |
Mr. John Thomas | General Counsel & Corporate Secretary | S.O. | S.O. | S.O. |
Mr. John Karakkal | Vice President of North American Sales & Marketing | S.O. | S.O. | S.O. |
Ms. Christine Wilson | Head of U.S. Sales and Marketing | S.O. | S.O. | S.O. |
Dr. Stephane Paquette Ph.D. | Vice President of Corporate Development | S.O. | S.O. | S.O. |
Mr. Josh Suskin | Director of Human Resources & Operations | S.O. | S.O. | S.O. |
Mr. Laurent Goux | Senior VP & GM of Europe | S.O. | S.O. | S.O. |
Mr. David Chien | Senior Vice President of Clinical Development | S.O. | S.O. | S.O. |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
L’ISS Governance QualityScore de Krystal Biotech, Inc. en date du 1 mai 2024 est 6. Les scores principaux sont Audit : 2; Société : 8; Droits des actionnaires : 8; Compensation : 5.